Which has higher valuation & earnings, ALKS or BHVN?

Alkermes has higher revenue and earnings than Biohaven. Biohaven is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alkermes $1.67B 4.09 $241.66M $0.38 106.87 Biohaven N/A N/A -$738.82M -$4.64 N/A

Is ALKS or BHVN more profitable?

Alkermes has a net margin of 3.96% compared to Biohaven's net margin of 0.00%. Alkermes' return on equity of 4.15% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Alkermes 3.96% 4.15% 2.19% Biohaven N/A -1,328.94% -138.27%

Does the media prefer ALKS or BHVN?

In the previous week, Alkermes had 1 more articles in the media than Biohaven. MarketBeat recorded 7 mentions for Alkermes and 6 mentions for Biohaven. Alkermes' average media sentiment score of 0.46 beat Biohaven's score of 0.44 indicating that Alkermes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biohaven 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, BHVN or IMVT?

Immunovant is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biohaven N/A N/A -$738.82M -$4.64 N/A Immunovant N/A N/A -$505.61M -$2.82 N/A

Is BHVN or IMVT more profitable?

Immunovant's return on equity of -69.59% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Biohaven N/A -1,328.94% -138.27% Immunovant N/A -69.59% -62.49%

Does the media refer more to BHVN or IMVT?

In the previous week, Immunovant had 8 more articles in the media than Biohaven. MarketBeat recorded 14 mentions for Immunovant and 6 mentions for Biohaven. Immunovant's average media sentiment score of 0.45 beat Biohaven's score of 0.44 indicating that Immunovant is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biohaven 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immunovant 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor RYTM or BHVN?

In the previous week, Biohaven had 4 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 6 mentions for Biohaven and 2 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.53 beat Biohaven's score of 0.44 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biohaven 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, BHVN or GRAL?

GRAIL has higher revenue and earnings than Biohaven. GRAIL is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biohaven N/A N/A -$738.82M -$4.64 N/A GRAIL $147.17M 42.67 -$408.35M -$9.75 N/A

Is BHVN or GRAL more profitable?

Biohaven has a net margin of 0.00% compared to GRAIL's net margin of -236.95%. GRAIL's return on equity of -15.88% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Biohaven N/A -1,328.94% -138.27% GRAIL -236.95% -15.88% -14.02%

Does the media refer more to BHVN or GRAL?

In the previous week, GRAIL had 12 more articles in the media than Biohaven. MarketBeat recorded 18 mentions for GRAIL and 6 mentions for Biohaven. Biohaven's average media sentiment score of 0.44 beat GRAIL's score of 0.38 indicating that Biohaven is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biohaven 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GRAIL 6 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Biohaven (BHVN) Competitors

$12.10 +0.18 (+1.47%)

Closing price 10/9/2026 03:59 PM Eastern

Extended Trading

$12.10 -0.01 (-0.08%)

As of 10/9/2026 07:30 PM Eastern

Compare

BHVN vs. ALKS, IMVT, KNSA, RYTM, and GRAL

Should you buy Biohaven stock or one of its competitors? Biohaven's main competitors and comparable companies include Alkermes (ALKS), Immunovant (IMVT), Kiniksa Pharmaceuticals International (KNSA), Rhythm Pharmaceuticals (RYTM), and GRAIL (GRAL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Biohaven compare to Alkermes?

Alkermes (NASDAQ:ALKS) and Biohaven (NYSE:BHVN) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

Alkermes has a net margin of 3.96% compared to Biohaven's net margin of 0.00%. Alkermes' return on equity of 4.15% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	3.96%	4.15%	2.19%
Biohaven	N/A	-1,328.94%	-138.27%

Alkermes currently has a consensus price target of $54.47, indicating a potential upside of 34.13%. Biohaven has a consensus price target of $18.69, indicating a potential upside of 54.38%. Given Biohaven's higher probable upside, analysts clearly believe Biohaven is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	1 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.74
Biohaven	2 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.59

95.2% of Alkermes shares are owned by institutional investors. Comparatively, 88.8% of Biohaven shares are owned by institutional investors. 4.6% of Alkermes shares are owned by company insiders. Comparatively, 13.8% of Biohaven shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Alkermes had 1 more articles in the media than Biohaven. MarketBeat recorded 7 mentions for Alkermes and 6 mentions for Biohaven. Alkermes' average media sentiment score of 0.46 beat Biohaven's score of 0.44 indicating that Alkermes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biohaven	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alkermes has higher revenue and earnings than Biohaven. Biohaven is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.67B	4.09	$241.66M	$0.38	106.87
Biohaven	N/A	N/A	-$738.82M	-$4.64	N/A

Alkermes has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market. Comparatively, Biohaven has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market.

Summary

Alkermes beats Biohaven on 12 of the 15 factors compared between the two stocks.

How does Biohaven compare to Immunovant?

Biohaven (NYSE:BHVN) and Immunovant (NASDAQ:IMVT) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings and profitability.

Immunovant's return on equity of -69.59% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-1,328.94%	-138.27%
Immunovant	N/A	-69.59%	-62.49%

88.8% of Biohaven shares are held by institutional investors. Comparatively, 47.1% of Immunovant shares are held by institutional investors. 13.8% of Biohaven shares are held by company insiders. Comparatively, 1.9% of Immunovant shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Immunovant is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$738.82M	-$4.64	N/A
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A

Biohaven has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market. Comparatively, Immunovant has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market.

Biohaven presently has a consensus price target of $18.69, indicating a potential upside of 54.38%. Immunovant has a consensus price target of $44.00, indicating a potential upside of 44.40%. Given Biohaven's stronger consensus rating and higher possible upside, analysts plainly believe Biohaven is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	2 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.59
Immunovant	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

In the previous week, Immunovant had 8 more articles in the media than Biohaven. MarketBeat recorded 14 mentions for Immunovant and 6 mentions for Biohaven. Immunovant's average media sentiment score of 0.45 beat Biohaven's score of 0.44 indicating that Immunovant is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biohaven	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunovant	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Biohaven beats Immunovant on 7 of the 13 factors compared between the two stocks.

How does Biohaven compare to Kiniksa Pharmaceuticals International?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Biohaven (NYSE:BHVN) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

Kiniksa Pharmaceuticals International presently has a consensus price target of $93.14, indicating a potential upside of 16.75%. Biohaven has a consensus price target of $18.69, indicating a potential upside of 54.38%. Given Biohaven's higher probable upside, analysts clearly believe Biohaven is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
Biohaven	2 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.59

Kiniksa Pharmaceuticals International has a beta of 0.04, indicating that its stock price is 96% less volatile than the broader market. Comparatively, Biohaven has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market.

Kiniksa Pharmaceuticals International has higher revenue and earnings than Biohaven. Biohaven is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$677.56M	9.19	$59.01M	$0.97	82.25
Biohaven	N/A	N/A	-$738.82M	-$4.64	N/A

54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. Comparatively, 88.8% of Biohaven shares are owned by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are owned by company insiders. Comparatively, 13.8% of Biohaven shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Biohaven had 4 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 6 mentions for Biohaven and 2 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 0.71 beat Biohaven's score of 0.44 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiniksa Pharmaceuticals International	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biohaven	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kiniksa Pharmaceuticals International has a net margin of 9.59% compared to Biohaven's net margin of 0.00%. Kiniksa Pharmaceuticals International's return on equity of 13.65% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%
Biohaven	N/A	-1,328.94%	-138.27%

Summary

Kiniksa Pharmaceuticals International beats Biohaven on 10 of the 15 factors compared between the two stocks.

How does Biohaven compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Biohaven (NYSE:BHVN) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

Rhythm Pharmaceuticals has a beta of 2.01, suggesting that its share price is 101% more volatile than the broader market. Comparatively, Biohaven has a beta of 1.35, suggesting that its share price is 35% more volatile than the broader market.

In the previous week, Biohaven had 4 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 6 mentions for Biohaven and 2 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.53 beat Biohaven's score of 0.44 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biohaven	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rhythm Pharmaceuticals currently has a consensus price target of $140.89, suggesting a potential upside of 55.20%. Biohaven has a consensus price target of $18.69, suggesting a potential upside of 54.38%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Rhythm Pharmaceuticals is more favorable than Biohaven.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.76
Biohaven	2 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.59

88.8% of Biohaven shares are held by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are held by insiders. Comparatively, 13.8% of Biohaven shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Biohaven has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -85.59%. Rhythm Pharmaceuticals' return on equity of -159.87% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%
Biohaven	N/A	-1,328.94%	-138.27%

Rhythm Pharmaceuticals has higher revenue and earnings than Biohaven. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	32.78	-$196.54M	-$3.11	N/A
Biohaven	N/A	N/A	-$738.82M	-$4.64	N/A

Summary

Rhythm Pharmaceuticals beats Biohaven on 10 of the 16 factors compared between the two stocks.

How does Biohaven compare to GRAIL?

Biohaven (NYSE:BHVN) and GRAIL (NASDAQ:GRAL) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability.

Biohaven has a net margin of 0.00% compared to GRAIL's net margin of -236.95%. GRAIL's return on equity of -15.88% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-1,328.94%	-138.27%
GRAIL	-236.95%	-15.88%	-14.02%

Biohaven has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market. Comparatively, GRAIL has a beta of 2.83, indicating that its stock price is 183% more volatile than the broader market.

Biohaven currently has a consensus target price of $18.69, suggesting a potential upside of 54.38%. GRAIL has a consensus target price of $102.70, suggesting a potential downside of 26.95%. Given Biohaven's stronger consensus rating and higher probable upside, analysts plainly believe Biohaven is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	2 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.59
GRAIL	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

GRAIL has higher revenue and earnings than Biohaven. GRAIL is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$738.82M	-$4.64	N/A
GRAIL	$147.17M	42.67	-$408.35M	-$9.75	N/A

In the previous week, GRAIL had 12 more articles in the media than Biohaven. MarketBeat recorded 18 mentions for GRAIL and 6 mentions for Biohaven. Biohaven's average media sentiment score of 0.44 beat GRAIL's score of 0.38 indicating that Biohaven is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biohaven	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GRAIL	6 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

88.8% of Biohaven shares are owned by institutional investors. 13.8% of Biohaven shares are owned by insiders. Comparatively, 1.8% of GRAIL shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Biohaven beats GRAIL on 10 of the 16 factors compared between the two stocks.

Get Biohaven News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BHVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BHVN vs. The Competition

Export

Metric	Biohaven	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$1.80B	$3.84B	$7.16B	$22.94B
Dividend Yield	N/A	3.66%	2.53%	3.72%
P/E Ratio	-2.61	13.42	274.15	28.60
Price / Sales	N/A	1,234.32	589.97	15.13
Price / Cash	N/A	116.56	76.38	37.72
Price / Book	31.04	17.17	11.21	4.72
Net Income	-$738.82M	-$22.69M	$3.50B	$1.07B
7 Day Performance	-6.01%	-1.33%	-0.90%	0.35%
1 Month Performance	-5.24%	-8.44%	-4.44%	-2.93%
1 Year Performance	-23.82%	14.02%	6.96%	9.26%

Biohaven Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BHVN Biohaven	3.6648 of 5 stars	$12.11 +1.5%	$18.69 +54.4%	-29.7%	$1.80B	N/A	N/A	274	News Coverage Analyst Forecast
ALKS Alkermes	3.2859 of 5 stars	$40.11 -3.2%	$54.47 +35.8%	+29.4%	$6.95B	$1.48B	105.56	2,050
IMVT Immunovant	2.5816 of 5 stars	$30.26 -5.6%	$44.00 +45.4%	+74.3%	$6.62B	N/A	N/A	315	Insider Trade
KNSA Kiniksa Pharmaceuticals International	4.0518 of 5 stars	$78.75 +1.0%	$93.14 +18.3%	+109.3%	$6.08B	$677.56M	81.19	366	Analyst Upgrade
RYTM Rhythm Pharmaceuticals	2.82 of 5 stars	$89.64 +1.3%	$140.89 +57.2%	-9.4%	$6.06B	$239.92M	N/A	414	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:BHVN) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biohaven (BHVN) Competitors